Sort by
Pharmacology, Toxicology and Pharmaceutical Science
Cetuximab
100%
Malignant Neoplasm
73%
Overall Survival
67%
Lung Cancer
62%
Chemotherapy
54%
Immune Checkpoint Inhibitor
50%
Cohort Study
50%
Non Small Cell Lung Cancer
37%
Neoplasm
34%
Progression Free Survival
34%
Paclitaxel
33%
Gemcitabine
33%
Renal Cell Carcinoma
33%
Synapsin I
33%
Epidermal Growth Factor Receptor 2
33%
Lung Adenocarcinoma
33%
Transcription Factor Nrf2
33%
Colon Carcinoma
33%
Bevacizumab
33%
Rituximab
33%
Combination Therapy
33%
Lactate Dehydrogenase
33%
Docetaxel
33%
Carcinogenesis
33%
Gamma Urogastrone
33%
Primary Tumor
33%
Gliclazide
16%
Maturity Onset Diabetes of the Young
16%
Hospital Mortality
12%
Herpes Zoster
11%
Pancreas Cancer
11%
Adverse Event
10%
Disease Exacerbation
8%
Colorectal Carcinoma
8%
Adenocarcinoma
8%
Abdominal Cancer
8%
Breast Cancer
8%
Squamous Cell Carcinoma
8%
Disease
8%
Clinical Trial
7%
Clinical Feature
6%
Survival Rate
6%
Messenger RNA
6%
Cytotoxic Chemotherapy
5%
Comorbidity
5%
Medicine and Dentistry
Chemotherapy
46%
Lung Tumor
33%
Metastatic Colorectal Cancer
33%
Prostate Cancer
33%
Microscopic Polyangiitis
33%
Burkitt's Lymphoma
33%
Tumor Embolism
33%
Rituximab
33%
Cetuximab
33%
Diffuse Large B-Cell Lymphoma
33%
International Prognostic Index
33%
Lactate Dehydrogenase
33%
Primary Tumor
33%
Colon Carcinoma
33%
Lung Cancer
29%
Overall Survival
26%
Neoplasm
19%
Pulmonary Fibrosis
16%
Cohort Analysis
16%
Immune Checkpoint Inhibitor
16%
Rectum Cancer
14%
Central Nervous System
13%
Hospital Mortality
12%
Multidetector Computed Tomography
11%
Diffusing Capacity
11%
Crackle
11%
Neutrophil Cytoplasmic Antibody
11%
Autoantibodies
11%
Renal Biopsy
11%
High-Resolution Computed Tomography
11%
Usual Interstitial Pneumonia
11%
Urinalysis
11%
Lung Function Test
11%
Colon
9%
Abdominal Cancer
8%
Colorectal Carcinoma
8%
Breast Cancer
8%
Malignant Neoplasm
7%
Survival Rate
6%
Non-Hodgkin Lymphoma
6%
Small Intestine
6%
Large Intestine
6%
Clinical Feature
6%
Cytotoxic Chemotherapy
5%
Erythrocyte Sedimentation Rate
5%
Livedo reticularis
5%
Hematuria
5%
Focal Segmental Glomerulosclerosis
5%
Comorbidity
5%
